Rituxan (rituximab) - Roche
Immune Reconstitution in Pediatric Patients Post Autologous Stem Cell Transplantation. (PubMed, Indian J Pediatr) - Sep 26, 2026 - "Pediatric ASCT recipients demonstrated predictable immune recovery; hypogammaglobulinemia at three months was confined to rituximab-exposed patients, supporting risk-stratified post-transplant immunoglobulin surveillance and revaccination." 
Journal • Bone Marrow Transplantation • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Neuroblastoma • Oncology • Pediatrics • Solid Tumor • Transplantation • CD4 • CD8
http://www.ncbi.nlm.nih.gov/pubmed/42789184
 
Aditya Kumar Gupta; Arjun Kurup; Deepam Pushpam; Jagdish Prasad Meena; Nupur Bathwar; Poonam Coshic; Pranay Tanwar; Rachna Seth; Rakesh Kumar Deepak; Sameer Bakhshi; Satyendra Batra; Sujata Mohanty
 
Sep 26, 2026
 
Prev Next